Core Insights - Windtree Therapeutics, Inc. has entered into a License and Supply Agreement with Evofem Biosciences, Inc. to become the sourcing partner for PHEXXI, a hormone-free contraceptive vaginal gel, aiming to generate profitable revenue [1][2][3] - PHEXXI's annual revenues exceeded $19 million in 2024, with over 96,000 boxes sold, indicating strong market demand [1] - The partnership aims to reduce manufacturing costs for PHEXXI, enabling Evofem to expand into price-sensitive global markets [2][3] Company Strategy - Windtree's new corporate strategy, announced in January 2025, focuses on becoming a revenue-generating biotech by advancing innovative therapies and establishing partnerships [3][4] - The company plans to leverage its global manufacturing contacts to significantly lower the cost of goods for PHEXXI, enhancing profitability [2][3] Product and Market Potential - PHEXXI is positioned as a first-in-class product that empowers women by providing a non-hormonal contraceptive option [1][3] - The anticipated reduction in manufacturing costs is expected to facilitate Evofem's entry into new international markets, addressing the need for affordable contraceptive options [3]
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product